How has Jyothy Laboratories Limited (JYOTHYLAB) been performing? We dig into revenue, profitability, valuation, and ownership trends.
Jyothy Lab Revenue Trend
Top-line growth continued for Jyothy Laboratories Limited, with FY2026 revenue reaching ₹2,944 Cr — a 3.4% increase over FY2025.
Looking at the longer trend, Jyothy Laboratories Limited's revenue grew from ₹1,647 Cr to ₹2,944 Cr at a 6.0% CAGR — moderate, consistent growth.
With a top line of ₹2,944 Cr, Jyothy Laboratories Limited operates at a mid-sized scale within the personal care sector.
Jyothy Laboratories Limited has posted revenue growth for 6 consecutive years — that's a sustained trend, not a one-off.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹2,944 Cr | +3.4% |
| FY2025 | ₹2,847 Cr | +3.3% |
| FY2024 | ₹2,757 Cr | +10.9% |
| FY2023 | ₹2,486 Cr | +13.2% |
| FY2022 | ₹2,196 Cr | — |
View Jyothy Laboratories Limited's full 10-year revenue trend with CAGR analysis →
Jyothy Lab Profitability
A 10.0% decline brought Jyothy Laboratories Limited's net profit down to ₹333 Cr in FY2026 from ₹370 Cr.
Net margin slipped from 13.0% to 11.3% in FY2026 — a sign of thinning profitability.
FY2026 diluted EPS of ₹9.07 was down from the ₹10.09 reported in FY2025.
Is Jyothy Lab Undervalued
Jyothy Laboratories Limited shares are currently trading at ₹206.06.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Jyothy Lab Shareholding Pattern
A stable promoter holding of 62.9% over 4 quarters suggests the management group is comfortable with its position.
Foreign institutions moved their stake up to 12.1% from 12.1% over the past year.
DII ownership is at 13.4%, down from the 16.1% recorded a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 62.9% | 12.1% | 13.4% | 11.6% |
| Mar 2026 | 62.9% | 12.3% | 14.6% | 10.1% |
| Dec 2025 | 62.9% | 12.8% | 15.1% | 9.2% |
| Sep 2025 | 62.9% | 12.1% | 16.1% | 8.9% |
Track quarterly shareholding changes for Jyothy Laboratories Limited →
Jyothy Lab Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹22.52B at the end of FY2026, down 16.3% from ₹26.91B a year earlier.
Other Assets is the largest block at 27.8%, followed by Cash & ST Investments at 24.8% and Property, Plant & Equipment at 15.8%.
Equity makes up 70.5% of liabilities and equity, with debt at 2.3% and operating liabilities at 27.2%. Over the year, debt is down 15.8% and equity is down 22.5%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 5.59B |
| Receivables | 2.57B |
| Inventories | 3.44B |
| Property, Plant & Equipment | 3.57B |
| Intangibles & Goodwill | 1.11B |
| Other Assets | 6.25B |
| Category | Value |
|---|---|
| Equity | 15.89B |
| Short-term Debt | 251.30M |
| Long-term Debt | 264.50M |
| Trade Payables | 3.17B |
| Other Liabilities | 2.96B |
Jyothy Lab at a Glance
Bringing the key threads together for Jyothy Laboratories Limited (JYOTHYLAB) as a personal care investment opportunity.
Revenue of ₹2,944 Cr in FY2026, up 3.4% year-over-year.
Long-term revenue has been compounding at 6.0% annually over 10 years.
The company is profitable, with a net margin of 11.3% and net income of ₹333 Cr.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Jyothy Laboratories Limited.